On July 14, Ali Health (00241.HK) fell 3.88% in regular trading, trading at HK$3.21, with turnover of approximately HK$93.82 million.

On the news front, the medical e-commerce sector weakened for a second consecutive session, with peers JD Health declining 4.31% and PA Good Doctor falling 5.21%, creating broad sector drag on Ali Health. Meanwhile, UBS previously maintained its sell rating on the stock and lowered its target price to HK$3.1, with FY2027-2029 earnings forecasts cut by 5%. The current share price has now converged closely toward that bearish target, sustaining downward pressure on valuation.

Adding to headwinds, southbound capital has cumulatively net sold over 128 million shares over the past 20 trading days, reflecting persistent institutional outflows that further weigh on sentiment. Despite robust FY2026 results showing revenue of RMB 34.26 billion (up 12%) and net profit growth of 35.2%, the stock remains under selling pressure as bearish analyst positioning and weak capital flows dominate near-term price action.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)